BiotechTube
Swiss Stem Cells Biotech

Swiss Stem Cells Biotech

Geneva, Switzerland· Est.
sscb-stembiotech.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Swiss Stem Cells Biotech AG is a pioneering Swiss biobank leveraging its FACT-NetCord and GMP certifications to provide high-quality, in-country stem cell preservation services. Its core business revolves around family banking for umbilical cord and adipose tissue-derived stem cells, complemented by a unique hybrid banking model that bridges private storage and public donation. The company has expanded its service portfolio to include DNA storage, immune cell preservation, and ATMP contract manufacturing, aiming to be a full-service partner in the regenerative medicine value chain. Founded in 2005 and headquartered in Geneva, SSCB combines rigorous Swiss regulatory standards with a strategic focus on both therapeutic applications and research.

Hematological DiseasesOrthopedicsRegenerative MedicineAesthetic Medicine

Technology Platform

Integrated GMP & FACT-NetCord accredited biobanking platform for processing and cryopreserving stem cells from umbilical cord blood/tissue, placental tissue, and adipose tissue, with expansion into PBMC storage and ATMP contract manufacturing.

Opportunities

The growth of the global regenerative medicine market and increasing acceptance of cell therapies drive demand for high-quality biobanking and manufacturing services.
SSCB's hybrid model and GMP certification uniquely position it to bridge private and public sectors and capture B2B revenue from the booming ATMP CDMO market.

Risk Factors

Regulatory changes in Switzerland or the EU could increase compliance costs or restrict services.
Market risks include competition from lower-cost international biobanks and ethical debates potentially reducing demand for private cord blood banking.
Long-term scientific uncertainty about the efficacy of stored cells for future novel therapies poses a credibility risk.

Competitive Landscape

SSCB competes with international private cord blood banks (e.g., Cryo-Save, Vita34) on the basis of its 100% Swiss-based, certified quality. Its hybrid model is a unique differentiator in the Swiss market. In ATMP manufacturing, it competes with larger global CDMOs and specialized cell therapy contract manufacturers.

More companies in Switzerland →